Emvododstat is an inhibitor of dihydroorotate dehydrogenase (DHODH).1 It inhibits DHODH by 89% in HeLa cells when used at a concentration of 100 nM. Emvododstat inhibits hypoxia-induced VEGF-A synthesis in HeLa cells (EC50 = 1.64 nM). It inhibits viral replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), hepatitis C virus (HCV) replicon genotype 1b, poliomyelitis virus, Rift Valley fever (RVF) virus, and Ebola virus in Vero, Huh7, HeLa, HeLa, and Vero 76 cells, respectively (EC50s = 2.6, 36, 0.57, 13, and 9.1 nM, respectively).2 Emvododstat inhibits production of IL-17F and IL-17A induced by CD3 and CD28 in Th17 cells in a concentration-dependent manner.
1.Cao, L., Weetall, M., Trotta, C., et al.Targeting of hematologic malignancies with PTC299, a novel potent inhibitor of dihydroorotate dehydrogenase with favorable pharmaceutical propertiesMol. Cancer Ther.18(1)3-16(2019) 2.Luban, J., Sattler, R.A., Mühlberger, E., et al.The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokinesVirus Res.292198246(2021)